Abstract: Objective To evaluate the efficacy and safety of sylibin in the treatment of patients with alcoholic liver disease（ALD）. Methods A systematic search of literatures in Cochrane Library,Pubmed,OVID,CNKI,VIP and Wanfang Database was performed,and randomized controlled trial（RCT） of silybin for ALD treatment were retrieved;RevMan 5.0 software was used for Meta-analysis. Results A total of 8 RCT trails involving 849 patients with ALD were included;The overall efficacy of silybin for ALD was better than that in the control group,with a OR-value of 5.49（95%CI=3.51-8.58,P<0.00001）;Between the silybin and the control group,the weighted mean differences（WMDs）for ALT,AST,and GGT were -6.20（95%CI -9.06 - -3.35）,-14.17（95% CI -17.08 - -11.25） and -32.32（95% CI -36.83 - -27.81）,respectively,and the WMDs for PT and ALB were 2.11（95%CI 0.64-3.57） and 1.42（95% CI 0.08 - 2.75）,respectively,while WMDs for TC and TG were -1.40（95% CI -1.61 - -1.19）and -0.35（95% CI -0.56 - -0.13）,respectively;The adverse effect rate in silybin group was 0.8%,while that in control group was 1.7%. Conclusion Silybin might be effective in improving liver function without clinically significant adverse effects in patients with ALD.